Department of Hematology, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, 241 -8515, Japan.
Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.
Ann Hematol. 2021 Nov;100(11):2763-2771. doi: 10.1007/s00277-021-04607-8. Epub 2021 Aug 6.
The efficacy and clinical significance of pre-conditioning intervention (PCI) before allogeneic hematopoietic cell transplantation (HCT) in patients with acute lymphoblastic leukemia (ALL) not in remission remain inconclusive. The purpose of this multicenter retrospective study was to clarify the clinical significance of PCI before HCT in patients with non-remission ALL. Patients with non-remission ALL who received HCT between 2005 and 2015 at 16 institutions were included. PCI was objectively defined and classified to three groups according to the intensity of PCI (no, intensive, or moderate). The study cohort consisted of 104 patients with a median age of 38 (range 17-68). A significant decrease of blast percentage in the peripheral blood (PB) was confirmed in both PCI groups, suggesting that PCIs were effective to stabilize the disease activity. The group with moderate PCI had higher nucleated cell count in the BM compared to the group with intensive PCI or the group without PCI. The overall survival (OS) rates of groups with intensive and no PCI showed comparable and significantly better compared to the group with moderate PCI (P = 0.009). Multivariate analysis demonstrated that the OS of moderate PCI group was significantly worse compared to that of intensive PCI group (HR = 2.43, 95% CI: 1.32-4.14, P = 0.004), while the OS of intensive PCI group was comparable to that of the group without PCI. These results suggest that the intensity of PCI rather than the response to PCI may contribute to improve the transplant outcome in patients with ALL not in remission.
预处理干预(PCI)在未缓解的急性淋巴细胞白血病(ALL)患者进行异基因造血细胞移植(HCT)前的疗效和临床意义仍不确定。本多中心回顾性研究的目的是阐明未缓解 ALL 患者 HCT 前 PCI 的临床意义。纳入了 2005 年至 2015 年在 16 家机构接受 HCT 的未缓解 ALL 患者。根据 PCI 的强度(无、强化或中度)客观定义和分类 PCI。研究队列包括 104 例患者,中位年龄为 38 岁(范围 17-68 岁)。在 PCI 组中均确认外周血(PB)中原始细胞百分比明显下降,表明 PCI 有效稳定疾病活动。与强化 PCI 组或无 PCI 组相比,中度 PCI 组的 BM 有核细胞计数更高。强化 PCI 组和无 PCI 组的总生存率(OS)明显优于中度 PCI 组(P=0.009)。多变量分析表明,中度 PCI 组的 OS 明显差于强化 PCI 组(HR=2.43,95%CI:1.32-4.14,P=0.004),而强化 PCI 组的 OS 与无 PCI 组相当。这些结果表明,PCI 的强度而不是对 PCI 的反应可能有助于改善未缓解 ALL 患者的移植结局。